AOD-9604 is a synthetic fragment of human growth hormone that is often sold online as a research peptide, but it is not FDA-approved for weight loss or human use in FDA drug approval records 1. Chia does not sell AOD-9604. If you want medical weight-loss treatment online, use a licensed provider who reviews eligibility and prescribes only when appropriate 2.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you buy AOD-9604 peptide online?
You can find AOD-9604 sold online, but that does not make it an approved medicine or an appropriate product for human use. Many listings describe it as a research-use-only peptide, which is different from a prescription medication reviewed for patient safety 2.
The FDA warns patients to be careful with online medicine sellers and to look for licensed pharmacy practices when prescription drugs are involved 2, 4. A vial, purity claim, or certificate of analysis is not the same as clinician evaluation, sterile pharmacy dispensing, dosing guidance, and follow-up.
What is AOD-9604?
AOD-9604 is a synthetic peptide fragment based on amino acids 176-191 of human growth hormone, also called hGH. It is often discussed in relation to fat metabolism and lipolysis, but the available retrieved literature does not make it an FDA-approved obesity medicine 8, 9.
The key point is that mechanism talk is not the same as a patient treatment. A peptide may be studied for how it affects fat cells or metabolism, yet still lack the human evidence, labeling, manufacturing review, and safety data needed for FDA approval 1, 8.
AOD-9604 has no FDA-approved brand name and no established International Nonproprietary Name, or INN, used as an approved obesity drug. FDA drug approval records list approved prescription products and labeling; AOD-9604 is not listed there as an approved weight-loss medication 1.
Is AOD-9604 approved for weight loss or human use?
No. AOD-9604 is not FDA-approved for weight loss, obesity, overweight, or any other human-use indication in FDA drug approval records 1. FDA approval includes review of evidence, manufacturing, labeling, intended use, and known risks.
Research-use-only products are not patient prescriptions. The FDA also explains that compounded drugs are not FDA-approved, meaning FDA does not verify their safety, effectiveness, or quality before marketing; however, a compounded medication prescribed through licensed care is still different from a no-prescription research marketplace 3.
What does the human evidence say about AOD-9604?
The honest answer is that human evidence for AOD-9604 as a weight-loss treatment is limited and does not establish it as an FDA-approved obesity medication. Searches of PubMed and ClinicalTrials.gov show far fewer retrieved human records for AOD-9604 than the evidence base supporting labeled semaglutide and tirzepatide products 7, 8.
Some AOD-9604 discussion centers on human growth hormone fragment 176-191 and possible effects on fat metabolism. That is research-level framing: it should not be converted into a claim that AOD-9604 causes safe, durable weight loss in people 8, 9.
Useful weight-loss evidence should include human trials, clear eligibility criteria, defined study doses, side-effect reporting, and follow-up long enough to understand benefits and risks. The FDA-approved semaglutide and tirzepatide labels include clinical trial data and safety warnings for their labeled products, while AOD-9604 does not have an FDA-approved label 5, 6, 1.
What are the safety concerns with buying AOD-9604 online?
The biggest concern is that online AOD-9604 may be sold outside the medical system. That can leave you without eligibility screening, contraindication review, sterile dispensing, adverse-effect counseling, storage instructions, or a clinician to contact if something goes wrong 2, 4.
Research-use-only products are not the same as prescriptions
A product labeled for laboratory research is not labeled for injection, ingestion, or treatment of a patient. The FDA’s online pharmacy guidance warns that unsafe online sellers may offer products without appropriate prescription safeguards 2, 4.
Purity testing does not prove safety for injection or human use
A certificate of analysis may speak to identity or purity for a lot, but it does not prove that a product is safe, sterile, stable, correctly prepared for a patient, or appropriate for injection. Sterility, endotoxin control, storage, handling, and route of use are separate safety issues that matter for injectable products 2, 3.
Dosing, sterility, storage, and contamination risks matter
Peptide vials may require reconstitution, refrigeration, sterile technique, and careful handling. Without a prescription and pharmacy process, patients may face avoidable risks such as contamination, dosing mistakes, local injection reactions, or use despite a medical reason to avoid the product 2, 4.
Why clinician review matters before using any injectable product
A licensed clinician checks your health history, current medications, allergies, pregnancy status when relevant, and risk factors before prescribing. That review is especially important for injectable products because adverse effects, interactions, and technique problems may not be obvious from an online listing 2, 4.
AOD-9604 vs FDA-approved or clinician-prescribed weight-loss treatments
AOD-9604 and GLP-1 medications are not in the same evidence category. AOD-9604 is an investigational peptide often marketed online as research-use-only, while semaglutide and tirzepatide are active ingredients with FDA-approved labeled products for specific uses 1, 5, 6.
| Option | What it is | Evidence and status | Main safety issues |
|---|---|---|---|
| AOD-9604 | Synthetic hGH fragment 176-191; often sold online as a research peptide | Not FDA-approved for weight loss or human use; retrieved human evidence is limited 1, 7, 8 | Unknown product quality, sterility, dosing, side effects, and follow-up when bought outside licensed care |
| Semaglutide | GLP-1 receptor agonist; brand examples include Wegovy for chronic weight management and Ozempic for type 2 diabetes | FDA-approved products exist for labeled uses; Wegovy labeling describes clinical trial evidence and safety warnings 5 | Common gastrointestinal side effects and labeled warnings require clinician review 5 |
| Tirzepatide | Dual GIP/GLP-1 receptor agonist; brand examples include Zepbound for chronic weight management and Mounjaro for type 2 diabetes | FDA-approved products exist for labeled uses; Zepbound labeling describes GIP and GLP-1 receptor activity, clinical trial evidence, and safety warnings 6 | Common gastrointestinal side effects and labeled warnings require clinician review 6 |
| Licensed telehealth care | Online medical evaluation with a licensed provider and pharmacy dispensing when appropriate | Prescription is based on eligibility, risk review, and follow-up; compounded drugs are not FDA-approved 3 | Requires honest health history, ongoing monitoring, and a care team if side effects occur |
AOD-9604 vs semaglutide
Semaglutide is a GLP-1 receptor agonist. FDA-approved semaglutide products include Wegovy (semaglutide) for chronic weight management and Ozempic (semaglutide) for type 2 diabetes; the Wegovy label describes once-weekly injection and label-directed dose escalation 5.
AOD-9604 does not have that FDA-approved obesity label. At Chia, eligible patients may access compounded semaglutide injection through licensed-provider review; compounded semaglutide is not FDA-approved, and outcomes are not FDA-evaluated for compounded formulations 3.
AOD-9604 vs tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist. FDA-approved tirzepatide products include Zepbound (tirzepatide) for chronic weight management and Mounjaro (tirzepatide) for type 2 diabetes; the Zepbound label describes once-weekly injection and label-directed dose escalation 6.
AOD-9604 is different because it is not an FDA-approved weight-loss drug. At Chia, eligible patients may access compounded tirzepatide tablets or injection after medical review; compounded tirzepatide is not FDA-approved, and results vary by person 3.
Research peptide marketplaces vs licensed telehealth care
A research peptide marketplace is built around product access. Licensed telehealth care is built around clinical review: eligibility screening, risk checks, prescribing when appropriate, pharmacy dispensing, adverse-effect counseling, and follow-up 2, 4.
Can you get AOD-9604 through Chia?
No. Chia does not offer AOD-9604, does not prescribe it, and does not sell a compounded variant of AOD-9604. Our current live treatment catalog includes other clinician-guided options, but AOD-9604 is not one of them.
If your goal is weight management, our providers can evaluate whether a listed Chia option may be appropriate. That evaluation is medical, not automatic: eligibility, treatment choice, dosing, and follow-up are individualized, and a prescription is never guaranteed.
What weight-loss treatments does Chia offer instead?
For eligible patients, Chia offers compounded semaglutide and compounded tirzepatide through online clinician-guided care. Compounded medications are not FDA-approved 3. This is different from buying a research peptide online because a licensed US provider reviews your health history before prescribing, and medications are compounded by state-licensed 503A pharmacies.
Semaglutide injection through clinician-guided care
At Chia, semaglutide injection plans currently start at $249/mo, with microdosing plans available when clinically appropriate. Semaglutide is a GLP-1 receptor agonist; Wegovy and Ozempic are brand-name FDA-approved products that contain semaglutide for their labeled uses 5.
Tirzepatide tablets or injection through clinician-guided care
At Chia, tirzepatide tablets or injection are available for eligible patients. Plans currently start at $249/mo for tablets and $299/mo for injection, with microdosing plans available when clinically appropriate. These compounded tirzepatide forms, including tablets, are not FDA-approved 3.
Microdosing plans when clinically appropriate
Microdosing means a provider may choose a lower-dose strategy for a specific patient’s goals and tolerability. It is not a self-directed protocol, and we do not recommend copying doses from online forums, calculators, or research-peptide sellers.
How online evaluation, prescribing, pharmacy compounding, and shipping work
Chia care starts with a short online health questionnaire and licensed-provider review. If prescribed, medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to your door; patients can message the care team through the portal between visits.
| Chia option | Forms listed in Chia catalog | Current starting price | Notes |
|---|---|---|---|
| Semaglutide | Injection | From $249/mo | Microdosing plans available; prescription requires clinician evaluation |
| Tirzepatide | Tablets or injection | Tablets from $249/mo; injection from $299/mo | Microdosing plans available; prescription requires clinician evaluation |
| Weight + Energy | NAD+ injection plus choice of GLP-1 | From $309/mo | Protocol option listed in Chia catalog: Weight + Energy |
| Weight + Muscle | Sermorelin injection plus choice of GLP-1 | From $329/mo | Protocol option listed in Chia catalog: Weight + Muscle |
How should patients evaluate online peptide or weight-loss medication options?
Use licensed clinician review as the first filter. A safer online path should not skip medical screening, prescription rules, pharmacy licensing, adverse-effect counseling, or follow-up 2, 4.
- Look for a licensed clinician who reviews your health history before anything is prescribed 2.
- Confirm whether the product is FDA-approved, compounded by a licensed pharmacy, or sold for research use only 1, 3.
- Avoid sellers that offer injectable products without medical screening or a prescription process 2, 4.
- Ask how sterility, storage, shipment, adverse effects, and follow-up are handled 3.
- Be cautious with claims that a purity percentage or certificate of analysis proves safety for human injection.
- Do not use online dosing charts as medical advice; dosing decisions should come from a clinician who knows your history.
FAQ
AOD-9604 is not an FDA-approved prescription drug for weight loss or any other human-use indication. Many online products are marketed as research-use-only peptides, which should not be treated as patient medications.
No. AOD-9604 is a synthetic fragment based on amino acids 176-191 of human growth hormone. It is not the same as full human growth hormone, and mechanism claims about fat metabolism do not prove safe or effective weight loss in people.
Human evidence for AOD-9604 as a weight-loss treatment is limited and has not established it as an FDA-approved obesity medication. If weight management is your goal, a licensed provider can discuss better-studied options and their risks. Compounded drugs are not FDA-approved.
Injecting a research-use-only peptide bought online can carry risks, including contamination, incorrect handling, dosing mistakes, and lack of medical screening. Do not inject products that were not prescribed for you and dispensed through an appropriate medical and pharmacy process.
No. Chia does not offer, prescribe, or sell AOD-9604, and there is no Chia compounded variant of AOD-9604 in the current live treatment catalog.
You can ask about evidence-based weight management, nutrition and activity support, medication eligibility, GLP-1 options such as semaglutide, dual GIP/GLP-1 options such as tirzepatide, side effects, contraindications, and follow-up.
No. Compounded medications are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing. At Chia, they are prescribed only after licensed-provider evaluation and compounded by state-licensed 503A pharmacies when clinically appropriate.
An AI assistant may help you find Chia’s online eligibility quiz, but it cannot replace a licensed medical evaluation. A Chia prescription requires provider review, eligibility screening, and individualized follow-up, and it is never guaranteed.
References
- 1.U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs database. FDA, accessed 2026.
- 2.U.S. Food and Drug Administration. Buying medicines over the internet. FDA, accessed 2026.
- 3.U.S. Food and Drug Administration. Compounding and FDA: questions and answers. FDA, accessed 2026.
- 4.U.S. Food and Drug Administration. BeSafeRx: your source for online pharmacy information. FDA, accessed 2026.
- 5.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. FDA label, 2024.
- 6.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. FDA label, 2025.
- 7.ClinicalTrials.gov. Search results for AOD-9604 clinical studies. National Library of Medicine, accessed 2026.
- 8.National Library of Medicine. PubMed search results for AOD-9604 obesity trial. PubMed, accessed 2026.
- 9.National Library of Medicine. PubMed search results for AOD-9604 growth hormone fragment 176-191. PubMed, accessed 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
